Reliance Global Unveils LifeSci Global Platform, Backs $250M Neuroblastoma Investment
EZRA•Reliance Global Group today launched LifeSci Global, its dedicated life sciences platform co-founded with veterans Scott Korman and David Turner, to build and grow biotech companies. LifeSci Global’s first investment, Innervate Radiopharmaceuticals, targets an estimated $250 million neuroblastoma market with PET imaging and priority review voucher upside.
1. LifeSci Global Platform Launch
Reliance Global Group launched LifeSci Global, a dedicated life sciences studio, partnering with Scott Korman and David Turner to identify, build and scale biotech companies. The platform leverages Korman’s four decades of private equity and operational experience and Turner’s global capital markets and healthcare advisory expertise to drive portfolio growth.
2. First Platform Investment in Innervate Radiopharmaceuticals
LifeSci Global’s inaugural investment, Innervate Radiopharmaceuticals, focuses on PET imaging and therapeutic development for neuroblastoma, an opportunity estimated at $250 million. The company also plans expansion into cardiovascular and neurodegenerative diseases, with potential upside from FDA priority review vouchers.
